Zura Bio (ZURA) announced the launch of TibuSHIELD, a global Phase 2 clinical study evaluating tibulizumab in adults with moderate to severe HS. TibuSHIELD is designed to enroll approximately 180 adults with moderate to severe HS across the United States, Canada, and Europe. The study will evaluate tibulizumab over a 28-week period, comprising a 16-week primary efficacy assessment and a 12-week safety follow-up, with an optional OLE. Topline results for the primary efficacy endpoint at Week 16 are expected in the third quarter of 2026.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZURA:
- Zura Bio price target lowered to $17 from $19 at Oppenheimer
- Zura Bio Reports Q1 2025 Financial Results
- Cautious Hold Rating for Zura Bio Amid Financial Challenges and Clinical Uncertainties
- Zura Bio price target lowered to $3 from $5 at H.C. Wainwright
- Zura Bio price target lowered to $19 from $20 at Oppenheimer